Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics

Editor Note: For more information about this release, please scroll to bottom.

Jan 14, 2014, 08:00 ET from Analysts' Corner

NEW YORK, January 14, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Antares Pharma, Inc. Research Report

On January 6, 2014, Antares Pharma, Inc. (Antares) announced its participation at the 32nd Annual J.P. Morgan Healthcare Conference. The Company informed that its President and CEO, Paul K. Wotton, Ph.D., is scheduled to present a corporate overview on January 16, 2014 at 1:00 p.m. PT at the conference. Antares added that a live webcast of the presentation and its replay will be available via the "Investor Relations" page of the website. The Full Research Report on Antares Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Quidel Corporation Research Report

On January 8, 2014, Quidel Corporation (Quidel) announced its preliminary revenue for Q4 2013. The Company stated that it expects revenues of approximately $50 million for Q4 2013. Douglas Bryant, President and CEO of Quidel, commented, "Despite low prevalence of influenza throughout most of the fourth quarter, we exceeded our forecast for our flu tests, driven by strong demand for Sofia Influenza A+B and lower than expected cannibalization of our QuickVue business. We are now more than half-way toward our goal of placing 10,000 Sofia analyzers by the end of this year, and remain very confident in our ability to reach that milestone." The Company added that it expects to release its Q4 2013 and full-year 2013 results in February 2014. The Full Research Report on Quidel Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


bluebird bio, Inc. Research Report

On January 9, 2014, bluebird bio, Inc. (bluebird bio) announced the appointment of James Mandell, M.D., to the Company's board of directors. The Company informed that Dr. Mandell was the CEO of Boston Children's Hospital and Children's Medical Center, from where he retired in October 2013, and serves on the board of the Franciscan's Hospital for Children and as Chair of the Board of the Harvard Risk Management Company. Nick Leschly, Chief bluebird bio, stated, "The bluebird team is excited to welcome Dr Mandell to our board. Jim's clear passion for patients, in particular kids in need, is a perfect fit with the company's vision and culture." In addition, bluebird bio also announced that Axel Polack, M.D., General Partner at TVM Capital Partners, has stepped down from the board. The Full Research Report on bluebird bio, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Given Imaging Ltd. Research Report

On January 2, 2014, Given Imaging Ltd. (Given) announced the results of a special shareholders' meeting held in Yoqneam, Israel on December 31, 2013, in which a total of c.22.4 million shares, or approximately 69.8%, of the total number of shares entitled to vote at the meeting were represented. The Company informed that during the meeting, all proposals were approved, except for Proposal 3 regarding equity grants to the Company's external directors which did not receive support from a majority of non-controlling shareholders, as required under Israeli law. The Full Research Report on Given Imaging Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Immunomedics, Inc. Research Report

On January 9, 2014, Immunomedics, Inc. (Immunomedics) announced the initiation of Phase III registration study of its pancreatic cancer drug, yttrium-90 ([90]Y)-clivatuzumab tetraxetan with the first patient dosing. The Company informed that PANcreatic Cancer RadioImmunotherapy Trial-1 (PANCRIT-1) is a double-blind, randomized study for evaluating the safety and efficacy of 90Y-clivatuzumab tetraxetan in combination with low-dose gemcitabine and best supportive care in patients with metastatic pancreatic cancer who have received at least two prior therapies, one of which must have been a gemcitabine-containing regimen. Cynthia L. Sullivan, President and CEO of Immunomedics stated, "This is a major milestone for the Company and for the clinical development of 90Yclivatuzumab tetraxetan. If the results from the Phase Ib study are confirmed by the PANCRIT-1 trial, clivatuzumab tetraxetan could become the first antibody-directed radiation therapy approved to treat patients with solid tumors. We plan to complete patient accrual in the first half of 2015." The Full Research Report on Immunomedics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner